SHANGHAI, CHINA - November 8, 2017 - Ark Biosciences Inc. (Ark), a clinical stage biotech company, announced today a collaboration with the California Institute for Biomedical Research (Calibr), an affiliate of The Scripps Research Institute (TSRI). This collaboration is to jointly develop novel first-in-class drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and related lung diseases.
Ark focuses on discovery and development of novel therapeutics to address unmet medical needs, especially in the area of viral infection and respiratory diseases. Its leading drug program, AK0529, is a potentially first-in-disease therapy for the treatment of respiratory syncytial virus (RSV) infection in pediatric and adult patient populations. It is currently undergoing a global phase 2 Proof-of-Concept clinical study in children hospitalized with RSV and is the leading program in the RSV drug development field. Ark has additional respiratory drug programs in its pipeline.
“We are delighted to partner with Ark Biosciences to further develop our novel small molecule drugs for the treatment of COPD. Ark will bring the same global standard to our joint development of respiratory drugs as it has in its exemplary anti-RSV drug program. We look forward to having a productive collaboration with Ark in this and other programs,” commented Dr. Matt Tremblay, COO of Calibr and VP of Business Development at TSRI.
“We are excited to collaborate with Calibr to develop novel and potentially first-in-class therapeutics for the treatment of COPD, a progressive lung disease with no cure. Our collaboration is based on the ground-breaking discovery at Calibr/TSRI recently published in Science. We will bring our expertise in the development of drugs for respiratory disease” said Dr. Jim Wu, CEO of Ark. He added, “Ark aims to be the gateway and preferred partner for global academic institutions, biotech and pharma companies to develop novel therapeutics that address major unmet medical needs for the global as well as Asian market.”
Chronic obstructive pulmonary disease (COPD) is a progressive obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. Tobacco smoking is the most common cause of COPD, with air pollution and genetics being contributing factors. Globally it affects approximately 300 million people, especially in older people. Each year it causes more than 3 million deaths and imposes an estimated economic cost of > $2.1 trillion. There is no known cure for COPD, which is always a progressive disease. The disease is currently managed by change in life style, preventive measures through reduction of exposure to risk factors, and medication that reduces symptoms.
About Ark Biosciences
Ark Biosciences is a privately held, clinical stage biotechnology company located in ZhangJiang Hi-Tech Park in Shanghai with its R&D Center in Suzhou, China, and offices in Australia and Switzerland. Ark has its own active R&D programs and licenses drug assets for clinical development in the Asia-Pacific region. Ark’s leading drug program, AK0529, a novel anti-RSV drug licensed from Roche Pharmaceutical, is currently in a global phase 2 PoC clinical trial. Through these efforts, Ark aims to be a global biotechnology company, discovering and developing novel therapeutics, especially in the areas of antiviral, pediatric, and respiratory disease. For more information, please visit: www.arkbiosciences.com
About Calibr and The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.
Ark Biosciences Contact:
Ms. Ping Cheng